In contrast, a low-dose of a recombinant properdin (more effective than native properdin in promoting complement activation via the alternative pathway) provided substantial protection against both Streptococcus pneumoniae (S. pneumonia) and Neisseria meningitides (N. meningitides) infections [92]. This evidence concerns the gene CFP and infection.